Iovance Biotherapeutics

ISIN US4622601007

 | 

WKN A2DT49

Market cap (in EUR)
888 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 888 m
EPS, EUR -1.09
P/B ratio 1.4
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 152 m
Net income, EUR -344 m
Profit margin -226.84%

What ETF is Iovance Biotherapeutics in?

There are 2 ETFs which contain Iovance Biotherapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Iovance Biotherapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.06%
Equity
United States
Health Care
Biotech
45
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.01%
Equity
United States
Small Cap
185
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.